Phenotyping results and levels of immunoglobulins in 3 patients before and after administration of rituximab
| Patient . | Day after BMT . | Day after Rituximab Administration . | Absolute Lymphocyte Count (×106/mL) . | Total CD19/20 Cells (×106/mL) . | Total CD3 Cells (×106/mL) . | Immunoglobulins at most recent follow-up (g/L)* . |
|---|---|---|---|---|---|---|
| UTN2110 | 411 | 174 | 2180 | 380 | 1350 | |
| 509 | 258 | 2368 | 497 | 1560 | ||
| 535 | 284 | 1716 | 480 | 1100 | IgG, 7.9; IgA, 0.7; IgM, 0.6 | |
| UTNJ23 | 248 | 124 | 2140 | 9 | 1370 | |
| 278 | 154 | 3050 | 2 | 700 | ||
| 311 | 187 | 1950 | <1 | 937 | ||
| 342 | 218 | 2880 | <2 | 1411 | IgG, 1.5; IgA, 0.004; IgM, 0.009 | |
| UTNJ34 | 189 | 115 | 490 | 3 | 264 | |
| 238 | 164 | 820 | 311 | 262 | ||
| 257 | 183 | 540 | 145 | 227 | ||
| 288 | 214 | 1050 | 283 | 546 | IgG, 11.9; IgA, 0.5; IgM, 0.9 |
| Patient . | Day after BMT . | Day after Rituximab Administration . | Absolute Lymphocyte Count (×106/mL) . | Total CD19/20 Cells (×106/mL) . | Total CD3 Cells (×106/mL) . | Immunoglobulins at most recent follow-up (g/L)* . |
|---|---|---|---|---|---|---|
| UTN2110 | 411 | 174 | 2180 | 380 | 1350 | |
| 509 | 258 | 2368 | 497 | 1560 | ||
| 535 | 284 | 1716 | 480 | 1100 | IgG, 7.9; IgA, 0.7; IgM, 0.6 | |
| UTNJ23 | 248 | 124 | 2140 | 9 | 1370 | |
| 278 | 154 | 3050 | 2 | 700 | ||
| 311 | 187 | 1950 | <1 | 937 | ||
| 342 | 218 | 2880 | <2 | 1411 | IgG, 1.5; IgA, 0.004; IgM, 0.009 | |
| UTNJ34 | 189 | 115 | 490 | 3 | 264 | |
| 238 | 164 | 820 | 311 | 262 | ||
| 257 | 183 | 540 | 145 | 227 | ||
| 288 | 214 | 1050 | 283 | 546 | IgG, 11.9; IgA, 0.5; IgM, 0.9 |
BMT indicates bone marrow transplantation.
Normal ranges are 6.4 to 13.4 g/L for IgG, 0.7 to 2.6 g/L for IgA, and 0.4 to 1.8 g/L for IgM.